Press Release Nov 28 2022
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release regarding its recent approval from the USFDA. The approval is for Levothyroxine Sodium for injection, which is indicated for treating myxedema coma. The drug will be manufactured at the company's facility in Jarod, India.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Nov 23 2022
- Press Release Nov 16 2022
- Press Release Nov 08 2022
- Press Release Nov 07 2022
- Press Release Nov 03 2022
Later from Zydus Lifesciences
- Press Release Dec 01 2022
- Press Release Dec 02 2022
- Press Release Dec 10 2022
- Press Release Dec 22 2022
- Loss of Share Certificates
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences